N/A
N=50
The Emotional and Functional Benefits of Poly-L-Lactic Acid
Facial Volume Loss
Bottom Line
View on ClinicalTrials.gov: NCT02613481 ↗Enrolled (actual)
50
Serious AEs
0.0%
Results posted
May 2019
Primary outcome: Primary: Mean Subject Self Reported Quality of Life Scale — 3.45 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Poly-L-Lactic Acid (Sculptra) injection (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Yardley Dermatology Associates
- Primary completion
- Jun 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Subject Self Reported Quality of Life Scale |
3.22 | — |
| PRIMARY Mean Rosenberg Self-Esteem Scale |
2.24 | — |
| PRIMARY Mean Rosenberg Self-Esteem Scale |
2.24 | — |
| PRIMARY Mean Subject Self Reported Quality of Life Scale |
3.22 | — |
Summary
This study will evaluates the emotional and functional benefits of Poly-L-Lactic Acid (Sculptra™), a cosmetic product used to fill defects of the skin. All participants will receive Sculptra™.
Eligibility Criteria
Inclusion Criteria
- Subject must be an outpatient, male or female subjects of any race, 35 years of age or older.
- Subject must have any degree of facial volume loss.
- Subjects of all Fitzpatrick skin types are eligible.
- Subject must be able to follow study instructions and likely to complete all required visits, as assessed by the Investigator.
- Subject must sign an IRB-approved Informed Consent form, Photographic Release Form, and the Authorization for Use and release of Health and Research Study Information (HIPAA) form prior to any study-related procedures being performed.
Exclusion Criteria
- Any of the previous facial treatments:
c. Any facial filler in the past 2 years d. Prior injection of permanent facial implant
- Have any skin pathology or condition that could interfere with the evaluation of the face.
- Be unable to communicate or cooperate with the Investigator due to a language barrier (non-English speaking), poor mental development, or impaired cerebral function.
- Have evidence of alcohol or drug abuse (Investigator opinion), or history of poor cooperation, non-compliance with medical treatment, or unreliability.
- Have used an investigational device, biologic or drug in the past 30 days, or be currently participating in an experimental drug, biologic or device trial.
- Have a condition or be in a situation that, in the Investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.
- Be an employee (or a relative of an employee) of the Investigator, Sponsor or representative of the Sponsor.
Data sourced from ClinicalTrials.gov (NCT02613481). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.